First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

August 21, 2025

Study Completion Date

August 21, 2025

Conditions
Advanced Solid Tumors Cancer
Interventions
DRUG

ABBV-CLS-579

Oral Capsule

DRUG

PD-1 inhibitor

Intravenous (IV) infusion

DRUG

VEGFR TKI

Oral Tablet

Trial Locations (17)

100

National Taiwan University Hospital, Taipei

15232

UPMC Hillman Cancer Center, Pittsburgh

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

Hospital Universitario HM Sanchinarro, Madrid

28078

Carolina BioOncology Institute, Huntersville

29010

Hospital Universitario Virgen de la Victoria, Málaga

33000

Hopital Saint-Andre, Bordeaux

46804

Fort Wayne Medical Oncology and Hematology, Fort Wayne

72762

Highlands Oncology Group Springdale, Springdale

94805

Institut Gustave Roussy, Villejuif

5262100

The Chaim Sheba Medical Center, Ramat Gan

06519

Yale University, New Haven

277-8577

National Cancer Center Hospital East, Kashiwa-Shi

641-8510

Wakayama Medical University Hospital, Wakayama

104-0045

National Cancer Center Hospital, Chuo-ku, Tokyo

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Calico Life Sciences LLC

INDUSTRY

lead

AbbVie

INDUSTRY